Latest News

VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.

October’s hematology coverage highlighted first-line pirtobrutinib, questions about myeloma treatment duration and early intervention, and pharmacists’ roles in medication safety and access.

October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.

Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.

ESMO 2026 lung cancer trials reshape first-line care with tarlatamab maintenance, stronger KRAS G12C results, and TROP2 ADC gains, raising pharmacy monitoring demands.

ESMO 2026 breast cancer updates show ribociclib boosts survival, while immunotherapy and extended endocrine therapy improve end points without longer overall survival.

A cohort study linked higher BMI and abdominal obesity to increased cancer risk in young adults, reinforcing the importance of early weight management.

Pharmacists can reduce COVID-19 vaccine hesitancy through honest, nonjudgmental communication and by using every patient touchpoint as an opportunity to offer vaccination.

Study shows prior authorization and high out-of-pocket costs drive prescription abandonment, limiting Medicare Part D blood cancer treatment access to oral anticancer medications.

From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.

Every-12-week immune checkpoint inhibitor dosing failed to establish noninferiority in the phase 3 MOIO trial, with an overall survival imbalance and no meaningful safety advantage over standard treatment.

Phase 3 data show pembrolizumab beats chemotherapy, offering durable first-line control with fewer severe toxicities and chemo-free potential.

From insurance delays to injection concerns, pharmacists can help patients navigate the first month and avoid preventable treatment interruptions.

In an interview with Pharmacy Times, Danielle Roman, PharmD, BCOP, FHOPA, discusses NCCN breast cancer guideline updates involving ESR1 mutation testing, targeted therapies, and pharmacists’ roles in monitoring, patient counseling, and treatment access.

Kidney Week 2026 posters show low-density lipoprotein cholesterol (LDL-C) fell by half in patients receiving dialysis, and oral enlicitide needed no dose adjustment for renal impairment.

Specialty pharmacy liaisons improve breast cancer care by easing access barriers, managing side effects, boosting adherence, and navigating new therapies and policies.

Walgreens adds virtual coverage navigation, Medicare GLP-1 Bridge support, and pharmacist follow-up calls as GLP-1 discontinuation remains high.

Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association, discusses pharmacists’ role in diabetes and CKD care at ASN Kidney Week 2026.

A helpful guide for pharmacists if teas, supplements, or cultural foods are part of a patient's regular routine.

Pharmacists can support effective cancer pain treatment by starting constipation prevention with opioid therapy and reassessing bowel function before symptoms become a barrier to care.

Six-year NATALEE data show adjuvant ribociclib (Kisqali) plus endocrine therapy improves overall survival in high-risk HR+/HER2- early breast cancer, with pharmacist-led monitoring.